Aroa Biosurgery (ASX:ARX) — Material Events

ASX:ARX · 9 articles in the last 12 months · 100% assessed

Click a band to jump to that tier

Major 1 article Significant 8 articles Not Assessed 0 articles
Major ≥90 Significant 75–89 Notable 50–74 Routine <50 Not assessed
Significant Score 75–89
8
Aroa Biosurgery Boosts Sales 14% and Returns to EBITDA Profit in H1 FY26Medium
Aroa Biosurgery H1 FY26 revenue up 14%, normalised EBITDA profit, reaffirms FY26 guidance
25 Nov 2025 ·Interim Financial Report ·85
Aroa Biosurgery Surpasses FY26 Targets with NZ$104m Revenue and Eyes FY27 GrowthMedium
Aroa Biosurgery FY26 revenue NZ$104m beats guidance; EBITDA NZ$13m; Myriad sales +54%; Symphony RCT success
26 May 2026 ·Full Year Results ·85
Aroa Biosurgery’s Symphony Trial Shows Promising Healing for Diabetic Foot UlcersMedium
Aroa Biosurgery completes Symphony RCT showing improved diabetic foot ulcer healing
30 Mar 2026 ·Clinical Trial Completion Announcement ·85
Not Assessed Low Score, or missing data
0

No articles in this tier for the last 12 months.